According to the company, data from a four-year post-implantation multi-center European study, performed in Greece, Poland and Austria, showed that Aorfix provides significant annual shrinkage (8% to 16%) of the aneurysm sac with no migration of the device.
To date, Aorfix has been successfully implanted into two patients and a further 15 implants are expected before the end of 2008, the company said.
Brian Howlett, CEO of Lombard Medical, said: “We are extremely pleased with the feedback received on Aorfix at the Veith Symposium, confirming the widely held view amongst clinicians that Aorfix is a versatile device which can be deployed in both routine and complex anatomies. It is also pleasing to obtain approval for Aorfix in Russia which is a growing market and will significantly increase the sales potential for Aorfix.”